World Bank Group & Moderna

World Bank Group: The World Bank Group contributed $160 million to the Democratic Republic of the Congo to aid in the Ebola response, playing a crucial role in funding the containment efforts.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

World Bank Group: The World Bank's Pandemic Fund announced up to $220.6 million in grants, providing significant financial support to the Ebola response.

Moderna: Moderna received up to $50 million from CEPI to support the preclinical and early clinical development of its mRNA-based Ebola Bundibugyo vaccine candidate, leveraging its mRNA platform for rapid response.

World Bank Group: The World Bank is listed as a partner in the urgent coordination meeting convened by Africa CDC, indicating potential involvement in the response to the Ebola outbreak.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

World Bank Group: The World Bank Group is involved in UK diplomatic visits but not central to the event.

Moderna: Moderna is a pharma company, not directly affected.